Acadia Pharmaceuticals (ACAD) EBITDA (2010 - 2026)

Acadia Pharmaceuticals' EBITDA history runs 17 years deep, the most recent figure standing at -$4.6 million for Q1 2026.

• In Q1 2026, EBITDA fell 123.93% year-over-year to -$4.6 million; the TTM figure through Mar 2026 stood at $80.9 million (down 65.55% YoY), while the FY2025 annual figure was $104.8 million, down 54.59% from the prior year.
• EBITDA for Q1 2026 stood at -$4.6 million, down from $17.4 million in the prior quarter.
• The five-year high for EBITDA was $153.5 million in Q4 2024, with the low at -$113.0 million in Q1 2022.
• The 5-year median for EBITDA is $15.2 million (2024), against an average of $2.0 million.
• The sharpest annual moves came in 2024 and 2026: EBITDA jumped 902.21% in 2024, then slumped 123.93% in 2026.
• Acadia Pharmaceuticals' EBITDA stood at -$46.1 million in 2022, then jumped by 175.86% to $34.9 million in 2023, then soared by 339.28% to $153.5 million in 2024, then slumped by 88.67% to $17.4 million in 2025, then sank by 126.54% to -$4.6 million in 2026.
• Business Quant data shows ACAD's EBITDA at -$4.6 million in Q1 2026, $17.4 million in Q4 2025, and $35.8 million in Q3 2025.